1. Reubi, J. C., & Waser, B. (2003). Concomitant expression of several peptide receptors in neuroendocrine tumors: Molecular basis for in vivo multireceptor tumour targeting. European Journal of Nuclear Medicine and Molecular Imaging, 30, 781–793.
2. Kulkarni, H. R., & Baum, R. P. (2014). Theranostics with Ga-68 somatostatin receptor PET/CT: Monitoring response to peptide receptor radionuclide therapy. PET Clinics, 9, 91–97.
3. Kulkarni, H. R., & Baum, R. P. (2014). Patient selection for personalized peptide receptor radionuclide therapy using Ga-68 somatostatin receptor PET/CT. PET Clinics, 9, 83–90.
4. Deppen, S. A., Liu, E., Blume, J. D., et al. (2016). Safety and efficacy of 68Ga DOTATATE PET/CT for diagnosis, staging, and treatment management of neuroendocrine tumors. Journal of Nuclear Medicine, 57, 708–714.
5. Antunes, P., Ginj, M., Zhang, H., Waser, B., Baum, R. P., Reubi, J. C., et al. (2007). Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? European Journal of Nuclear Medicine and Molecular Imaging, 34, 982–993.
6. Ambrosini, V., et al. (2012). 68Ga-labelled peptides for diagnosis of gastroenteropancreatic NET. European Journal of Nuclear Medicine and Molecular Imaging, 39, S52–S60.
7. Buchmann, I., Henze, M., Engelbrecht, S., Eisenhut, M., Runz, A., Schäfer, M., et al. (2007). Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. European Journal of Nuclear Medicine and Molecular Imaging, 34, 1617–1626.
8. Krausz, Y., Freedman, N., Rubinstein, R., Lavie, E., Orevi, M., Tshori, S., et al. (2011). 68Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: Comparison with 111In-DTPA-octreotide (OctreoScan®). Molecular Imaging and Biology, 13, 583–593.
9. Naswa, N., Sharma, P., Kumar, A., Nazar, A. H., Kumar, R., Chumber, S., et al. (2011). Gallium-68-DOTA-NOC PET/CT of patients with gastroenteropancreatic neuroendocrine tumors: A prospective single-center study. American Journal of Roentgenology, 197, 1221–1228.
10. Hofman, M. S., Kong, G., Neels, O. C., Eu, P., Hong, E., & Hicks, R. J. (2012). High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours. Journal of Medical Imaging and Radiation Oncology, 56, 40–47.
11. Ambrosini, V., Campana, D., Bodei, L., et al. (2010). 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. Journal of Nuclear Medicine, 51, 669–673.
12. Herrmann, K., Czernin, J., Wolin, E. M., et al. (2015). Impact of 68Ga-DOTATATE PET/CT on the management of neuroendocrine tumors: The referring physician’s perspective. Journal of Nuclear Medicine, 56, 70–75.
13. Skoura, E., Michopoulou, S., Mohmaduvesh, M., et al. (2016). The impact of 68Ga-DOTATATE PET/CT imaging on management of patients with neuroendocrine tumors: Experience from a National Referral Center in the United Kingdom. Journal of Nuclear Medicine, 57, 34–40.
14. Kratochwil, C., Stefanova, M., Mavriopoulou, E., et al. (2015). SUV of [68Ga]DOTATOC-PET/CT predicts response probability of PRRT in neuroendocrine tumors. Molecular Imaging and Biology, 17, 313–318.
15. Kayani, I., Bomanji, J. B., Groves, A., Conway, G., Gacinovic, S., Win, T., et al. (2008). Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG. Cancer, 112(11), 2447–2455.
16. Oh, S., Prasad, V., Lee, D. S., & Baum, R. P. (2011). Effect of peptide receptor radionuclide therapy on somatostatin receptor status and glucose metabolism in neuroendocrine tumors: Intraindividual comparison of Ga-68 DOTANOC PET/CT and F-18 FDG PET/CT. International Journal of Molecular Imaging, 2011.
17. Gabriel, M., Oberaurl, A., Dobrozemskyl, G., et al. (2009). 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy. Journal of Nuclear Medicine, 50, 1427–1434.
18. Garcia-Carbonero, R., et al. (2015). Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): Current perspectives and future trends of an exciting field in development. Cancer Metastasis Reviews, 34, 823–842.

Pasted text(43).txt

Document

Got it — this uploaded list has 77 references. I’ll keep the same order and numbering, and convert it to APA 7 style.

Thought for a couple of seconds

Here is the reference list converted into APA 7th edition style, keeping the original order and numbering. This list has 77 references.

References

1. Lieberman, P. M. (2014). Epstein-Barr virus turns 50. Science, 343(6177), 1323–1325. https://doi.org/10.1126/science.1252786
2. Young, L. S., Yap, L. F., & Murray, P. G. (2016). Epstein-Barr virus: More than 50 years old and still providing surprises. Nature Reviews Cancer, 16(12), 789–802. https://doi.org/10.1038/nrc.2016.92
3. Cohen, J. I., Mocarski, E. S., Raab-Traub, N., Corey, L., & Nabel, G. J. (2013). The need and challenges for development of an Epstein-Barr virus vaccine. Vaccine, 31(Suppl. 2), B194–B196. https://doi.org/10.1016/j.vaccine.2012.09.041
4. Teow, S. Y., & Peh, S. C. (2017). Exosomes as the promising biomarker for Epstein-Barr virus (EBV)-associated cancers. In J. Wang (Ed.), Novel implications of exosomes in diagnosis and treatment of cancer and infectious diseases. InTech.
5. Tsao, S.-W., Tsang, C. M., To, K.-F., & Lo, K.-W. (2014). The role of Epstein-Barr virus in epithelial malignancies. The Journal of Pathology, 235(2), 323–333. https://doi.org/10.1002/path.4448
6. Tsao, S. W., Tramoutanis, G., Dawson, C. W., Lo, A. K. F., & Huang, D. P. (2002). The significance of LMP1 expression in nasopharyngeal carcinoma. Seminars in Cancer Biology, 12(6), 473–487. https://doi.org/10.1016/S1044-579X(02)00090-1
7. Kong, Q.-L., Hu, L.-J., Cao, J.-Y., Huang, Y.-J., Xu, L.-H., Liang, Y., Xiong, D., Guan, S., Guo, B.-H., Mai, H.-Q., Chen, Q.-Y., Zhang, X., Li, M.-Z., Shao, J.-Y., Qian, C.-N., Xia, Y.-F., Song, L.-B., Zeng, Y.-X., & Zeng, M.-S. (2010). Epstein-Barr virus-encoded LMP2A induces an epithelial-mesenchymal transition and increases the number of side population stem-like cancer cells in nasopharyngeal carcinoma. PLoS Pathogens, 6(6). https://doi.org/10.1371/journal.ppat.1000940
8. Kang, M. S., & Kieff, E. (2015). Epstein-Barr virus latent genes. Experimental & Molecular Medicine, 47(1).
9. Hu, L., Lin, Z., Wu, Y., Dong, J., Zhao, B., Cheng, Y., Huang, P., Xu, L., Xia, T., Xiong, D., Wang, H., Li, M., Guo, L., Kieff, E., Zeng, Y., Zhong, Q., & Zeng, M. (2016). Comprehensive profiling of EBV gene expression in nasopharyngeal carcinoma through paired-end transcriptome sequencing. Frontiers of Medicine, 10(1), 61–75. https://doi.org/10.1007/s11684-016-0436-0
10. Huang, S.-Y., Fang, C.-Y., Tsai, C.-H., Chang, Y., Takada, K., Hsu, T.-Y., & Chen, J.-Y. (2010). N-methyl-N′-nitro-N-nitrosoguanidine induces and cooperates with 12-O-tetradecanoylphorbol-1,3-acetate/sodium butyrate to enhance Epstein-Barr virus reactivation and genome instability in nasopharyngeal carcinoma cells. Chemico-Biological Interactions, 188(3), 623–634. https://doi.org/10.1016/j.cbi.2010.09.020
11. Hong, G. K., Kumar, P., Wang, L., Damania, B., Gulley, M. L., Delecluse, H.-J., Polverini, P. J., & Kenney, S. C. (2005). Epstein-Barr virus lytic infection is required for efficient production of the angiogenesis factor vascular endothelial growth factor in lymphoblastoid cell lines. Journal of Virology, 79(22), 13984–13992. https://doi.org/10.1128/JVI.79.22.13984-13992.2005
12. Li, H., Liu, S., Hu, J., Luo, X., Li, N., Bode, A. M., & Cao, Y. (2016). Epstein-Barr virus lytic reactivation regulation and its pathogenic role in carcinogenesis. International Journal of Biological Sciences, 12(11), 1309–1318. https://doi.org/10.7150/ijbs.16564
13. Stoker, S. D., Novalić, Z., Wildeman, M. A., Huitema, A. D. R., Verkuijlen, S. A. W. M., Juwana, H., Greijer, A. E., Tan, I. B., Middeldorp, J. M., & de Boer, J. P. (2015). Epstein-Barr virus-targeted therapy in nasopharyngeal carcinoma. Journal of Cancer Research and Clinical Oncology, 141(10), 1845–1857. https://doi.org/10.1007/s00432-015-1969-3
14. Cao, Y. (2017). EBV based cancer prevention and therapy in nasopharyngeal carcinoma. NPJ Precision Oncology, 1(1). https://doi.org/10.1038/s41698-017-0018-x
15. Lutzky, V. P., Crooks, P., Morrison, L., Stevens, N., Davis, J. E., Corban, M., Hall, D., Panizza, B., Coman, W. B., Coman, S., & Moss, D. J. (2014). Cytotoxic T cell adoptive immunotherapy as a treatment for nasopharyngeal carcinoma. Clinical and Vaccine Immunology, 21(2), 256–259. https://doi.org/10.1128/CVI.00121-13
16. Lin, M.-C., Lin, Y.-C., Chen, S.-T., Young, T.-H., & Lou, P.-J. (2017). Therapeutic vaccine targeting Epstein-Barr virus latent protein, LMP1, suppresses LMP1-expressing tumor growth and metastasis in vivo. BMC Cancer, 17(1), Article 18. https://doi.org/10.1186/s12885-016-3027-1
17. Taylor, G. S., & Steven, N. M. (2016). Therapeutic vaccination strategies to treat nasopharyngeal carcinoma. Chinese Clinical Oncology, 5(2), Article 23. https://doi.org/10.21037/cco.2016.03.20
18. Cohen, J. I. (2015). Epstein-Barr virus vaccines. Clinical & Translational Immunology, 4(1).
19. Taylor, G. S., Jia, H., Harrington, K., Lee, L. W., Turner, J., Ladell, K., Price, D. A., Tanday, M., Matthews, J., Roberts, C., Edwards, C., McGuigan, L., Hartley, A., Wilson, S., Hui, E. P., Chan, A. T. C., Rickinson, A. B., & Steven, N. M. (2014). A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr virus (EBV) target antigens: A phase I trial in UK patients with EBV-positive cancer. Clinical Cancer Research, 20(19), 5009–5022. https://doi.org/10.1158/1078-0432.CCR-14-1122-T
20. Hui, E. P., Taylor, G. S., Jia, H., Ma, B. B. Y., Chan, S. L., Ho, R., Wong, W.-L., Wilson, S., Johnson, B. F., Edwards, C., Stocken, D. D., Rickinson, A. B., Steven, N. M., & Chan, A. T. C. (2013). Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients. Cancer Research, 73(6), 1676–1688. https://doi.org/10.1158/0008-5472.CAN-12-2448
21. Wu, J., Xu, D., Cheng, Q., Zhang, L., Cheng, D., & Zhao, J. (2017). EBV LMP1 regulates cancer growth through IRF-7 in nasopharyngeal carcinoma. Journal of Molecular Oncology Research, 1(1), 47–52.
22. Port, R. J., Pinheiro-Maia, S., Hu, C., Arrand, J. R., Wei, W., Young, L. S., & Dawson, C. W. (2013). Epstein-Barr virus induction of the Hedgehog signalling pathway imposes a stem cell phenotype on human epithelial cells. The Journal of Pathology, 231(3), 367–377. https://doi.org/10.1002/path.4245
23. Dawson, C. W., Port, R. J., & Young, L. S. (2012). The role of the EBV-encoded latent membrane proteins LMP1 and LMP2 in the pathogenesis of nasopharyngeal carcinoma (NPC). Seminars in Cancer Biology, 22(2), 144–153. https://doi.org/10.1016/j.semcancer.2012.01.004
24. Horikawa, T., Sheen, T.-S., Takeshita, H., Sato, H., Furukawa, M., & Yoshizaki, T. (2001). Induction of c-met proto-oncogene by Epstein-Barr virus latent membrane protein-1 and the correlation with cervical lymph node metastasis of nasopharyngeal carcinoma. The American Journal of Pathology, 159(1), 27–33. https://doi.org/10.1016/S0002-9440(10)61669-0
25. Lan, Y.-Y., Hsiao, J.-R., Chang, K.-C., Chang, J. S.-M., Chen, C.-W., Lai, H.-C., Wu, S.-Y., Yeh, T.-H., Chang, F.-H., Lin, W.-H., Su, I.-J., & Chang, Y. (2012). Epstein-Barr virus latent membrane protein 2A promotes invasion of nasopharyngeal carcinoma cells through ERK/Fra-1-mediated induction of matrix metalloproteinase 9. Journal of Virology, 86(12), 6656–6667. https://doi.org/10.1128/JVI.00174-12
26. Fotheringham, J. A., Coalson, N. E., & Raab-Traub, N. (2012). Epstein-Barr virus latent membrane protein-2A induces ITAM/Syk- and Akt-dependent epithelial migration through αV-integrin membrane translocation. Journal of Virology, 86(19), 10308–10320. https://doi.org/10.1128/JVI.00853-12
27. Fotheringham, J. A., Mazzucca, S., & Raab-Traub, N. (2010). Epstein-Barr virus latent membrane protein-2A-induced ΔNp63α expression is associated with impaired epithelial-cell differentiation. Oncogene, 29(30), 4287–4296. https://doi.org/10.1038/onc.2010.175
28. Fukuda, M., & Longnecker, R. (2004). Latent membrane protein 2A inhibits transforming growth factor-β1-induced apoptosis through the phosphatidylinositol 3-kinase/Akt pathway. Journal of Virology, 78(4), 1697–1705. https://doi.org/10.1128/JVI.78.4.1697-1705.2004
29. Moody, G. A., Scott, R. S., Amirghahari, N., Nathan, C.-A., Young, L. S., Dawson, C. W., & Sixbey, J. W. (2005). Modulation of the cell growth regulator mTOR by Epstein-Barr virus-encoded LMP2A. Journal of Virology, 79(9), 5499–5506. https://doi.org/10.1128/JVI.79.9.5499-5506.2005
30. Frappier, L. (2012). Role of EBNA1 in NPC tumourigenesis. Seminars in Cancer Biology, 22(2), 154–161. https://doi.org/10.1016/j.semcancer.2011.12.002
31. Sivachandran, N., Sarkari, F., & Frappier, L. (2008). Epstein-Barr nuclear antigen 1 contributes to nasopharyngeal carcinoma through disruption of PML nuclear bodies. PLoS Pathogens, 4(10), e1000170. https://doi.org/10.1371/journal.ppat.1000170
32. Wood, V. H. J., O’Neil, J. D., Wei, W., Stewart, S. E., Dawson, C. W., & Young, L. S. (2007). Epstein-Barr virus-encoded EBNA1 regulates cellular gene transcription and modulates the STAT1 and TGFβ signaling pathways. Oncogene, 26(28), 4135–4147. https://doi.org/10.1038/sj.onc.1210496
33. Cao, J. Y., Mansouri, S., & Frappier, L. (2012). Changes in the nasopharyngeal carcinoma nuclear proteome induced by the EBNA1 protein of Epstein-Barr virus reveal potential roles for EBNA1 in metastasis and oxidative stress responses. Journal of Virology, 86(1), 382–394. https://doi.org/10.1128/JVI.05648-11
34. Hsu, M., Wu, S.-Y., Chang, S.-S., Su, I.-J., Tsai, C.-H., Lai, S.-J., Shiau, A.-L., Takada, K., & Chang, Y. (2008). Epstein-Barr virus lytic transactivator Zta enhances chemotactic activity through induction of interleukin-8 in nasopharyngeal carcinoma cells. Journal of Virology, 82(7), 3679–3688. https://doi.org/10.1128/JVI.02301-07
35. Wu, C.-C., Liu, M.-T., Chang, Y.-T., Fang, C.-Y., Chou, S.-P., Liao, H.-W., Kuo, K.-L., Hsu, S.-L., Chen, Y.-R., Wang, P.-W., Chen, Y.-L., Chuang, H.-Y., Lee, C.-H., Chen, M., Wayne Chang, W.-S., & Chen, J.-Y. (2009). Epstein-Barr virus DNase (BGLF5) induces genomic instability in human epithelial cells. Nucleic Acids Research, 38(6), 1932–1949. https://doi.org/10.1093/nar/gkp1169
36. Chiu, S.-H., Wu, C.-C., Fang, C.-Y., Yu, S.-L., Hsu, H.-Y., Chow, Y.-H., & Chen, J.-Y. (2014). Epstein-Barr virus BALF3 mediates genomic instability and progressive malignancy in nasopharyngeal carcinoma. Oncotarget, 5(18), 8583–8601. https://doi.org/10.18632/oncotarget.2323
37. Takada, K. (2012). Role of EBER and BARF1 in nasopharyngeal carcinoma (NPC) tumorigenesis. Seminars in Cancer Biology, 22(2), 162–165. https://doi.org/10.1016/j.semcancer.2011.12.007
38. Elgui de Oliveira, D., Müller-Coan, B. G., & Pagano, J. S. (2016). Viral carcinogenesis beyond malignant transformation: EBV in the progression of human cancers. Trends in Microbiology, 24(8), 649–664. https://doi.org/10.1016/j.tim.2016.03.008
39. Smith, C., Wakisaka, N., Crough, T., Peet, J., Yoshizaki, T., Beagley, L., & Khanna, R. (2009). Discerning regulation of cis- and trans-presentation of CD8+ T-cell epitopes by EBV-encoded oncogene LMP-1 through self-aggregation. Blood, 113(24), 6148–6152. https://doi.org/10.1182/blood-2009-02-203687
40. Frappier, L. (2015). EBNA1. Current Topics in Microbiology and Immunology, 391, 3–34. https://doi.org/10.1007/978-3-319-22834-1_1
41. Bickham, K., Münz, C., Tsang, M. L., Larsson, M., Fonteneau, J.-F., Bhardwaj, N., & Steinman, R. (2001). EBNA1-specific CD4+ T cells in healthy carriers of Epstein-Barr virus are primarily Th1 in function. The Journal of Clinical Investigation, 107(1), 121–130. https://doi.org/10.1172/JCI10209
42. Lee, S. P., Brooks, J. M., Al-Jarrah, H., Thomas, W. A., Haigh, T. A., Taylor, G. S., Humme, S., Schepers, A., Hammerschmidt, W., Yates, J. L., Rickinson, A. B., & Blake, N. W. (2004). CD8 T cell recognition of endogenously expressed Epstein-Barr virus nuclear antigen 1. The Journal of Experimental Medicine, 199(10), 1409–1420. https://doi.org/10.1084/jem.20040121
43. Tsai, M.-H., Raykova, A., Klinke, O., Bernhardt, K., Gärtner, K., Leung, C., Geletneky, K., Sertel, S., Münz, C., Feederle, R., & Delecluse, H.-J. (2013). Spontaneous lytic replication and epitheliotropism define an Epstein-Barr virus strain found in carcinomas. Cell Reports, 5(2), 458–470. https://doi.org/10.1016/j.celrep.2013.09.012
44. Lin, X., Tsai, M.-H., Shumilov, A., Poirey, R., Bannert, H., Middeldorp, J. M., Feederle, R., & Delecluse, H.-J. (2015). The Epstein-Barr virus BART miRNA cluster of the M81 strain modulates multiple functions in primary B cells. PLoS Pathogens, 11(12), e1005344. https://doi.org/10.1371/journal.ppat.1005344
45. Tsai, M.-H., Lin, X., Shumilov, A., Bernhardt, K., Feederle, R., Poirey, R., Kopp-Schneider, A., Pereira, B., Almeida, R., & Delecluse, H.-J. (2017). The biological properties of different Epstein-Barr virus strains explain their association with various types of cancers. Oncotarget, 8(6), 10238–10254. https://doi.org/10.18632/oncotarget.14380
46. Hui, K. F., Ho, D. N., Tsang, C. M., Middeldorp, J. M., Tsao, G. S. W., & Chiang, A. K. S. (2012). Activation of lytic cycle of Epstein-Barr virus by suberoylanilide hydroxamic acid leads to apoptosis and tumor growth suppression of nasopharyngeal carcinoma. International Journal of Cancer, 131(8), 1930–1940. https://doi.org/10.1002/ijc.27439
47. Choi, C. K., Ho, D. N., Hui, K. F., Kao, R. Y., & Chiang, A. K. S. (2015). Identification of novel small organic compounds with diverse structures for the induction of Epstein-Barr virus (EBV) lytic cycle in EBV-positive epithelial malignancies. PLoS ONE, 10(12), e0145994. https://doi.org/10.1371/journal.pone.0145994
48. Novalić, Z., Rossen, T. M., Greijer, A. E., & Middeldorp, J. M. (2016). Agents and approaches for lytic induction therapy of Epstein-Barr virus associated malignancies. Medicinal Chemistry, 6, 449–466.
49. Louis, C. U., Straath, K., Bollard, C. M., Gerken, C., Huls, M. H., Gresik, M. V., Wu, M.-F., Weiss, H. L., Gee, A. P., Brenner, M. K., Rooney, C. M., Heslop, H. E., & Gottschalk, S. (2009). Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients. Blood, 113(11), 2442–2450. https://doi.org/10.1182/blood-2008-05-157222
50. Jain, A., Chia, W. K., & Toh, H. C. (2016). Immunotherapy for nasopharyngeal cancer: A review. Chinese Clinical Oncology, 5(2), Article 22. https://doi.org/10.21037/cco.2016.03.08
51. Louis, C. U., Straathof, K., Bollard, C. M., et al. (2010). Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma. Journal of Immunotherapy, 33(9), 983–990.
52. Secondino, S., Zecca, M., Licitra, L., Gurrado, A., Schiavetto, I., Bossi, P., Locati, L., Schiavo, R., Basso, S., Baldanti, F., Maccario, R., Locatelli, F., Siena, S., Pedrazzoli, P., & Comoli, P. (2012). T-cell therapy for EBV-associated nasopharyngeal carcinoma: Preparative lymphodepleting chemotherapy does not improve clinical results. Annals of Oncology, 23(2), 435–441. https://doi.org/10.1093/annonc/mdr134
53. Smith, C., Lee, V., Schuessler, A., Beagley, L., Rehan, S., Tsang, J., Li, V., Tiu, R., Smith, D., Neller, M. A., Matthews, K. K., Gostick, E., Price, D. A., Burrows, J., Boyle, G. M., Chua, D., Panizza, B., Porceddu, S. V., Nicholls, J., Kwong, D., & Khanna, R. (2017). Pre-emptive and therapeutic adoptive immunotherapy for nasopharyngeal carcinoma: Phenotype and effector function of T cells impact on clinical response. OncoImmunology, 6(2), e1273311. https://doi.org/10.1080/2162402X.2016.1273311
54. Smith, C., Tsang, J., Beagley, L., Chua, D., Lee, V., Li, V., Moss, D. J., Coman, W., Chan, K. H., Nicholls, J., Kwong, D., & Khanna, R. (2012). Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy. Cancer Research, 72(5), 1116–1125. https://doi.org/10.1158/0008-5472.CAN-11-3399
55. Chia, W.-K., Teo, M., Wang, W.-W., Lee, B., Ang, S.-F., Tai, W.-M., Chee, C.-L., Ng, J., Kan, R., Lim, W.-T., Tan, S.-H., Ong, W.-S., Cheung, Y.-B., Tan, E.-H., Connolly, J. E., Gottschalk, S., & Toh, H.-C. (2014). Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma. Molecular Therapy, 22(1), 132–139. https://doi.org/10.1038/mt.2013.242
56. Chia, W. K., Wang, W.-W., Teo, M., Tai, W. M., Lim, W. T., Tan, E. H., Leong, S. S., Sun, L., Chen, J. J., Gottschalk, S., & Toh, H. C. (2012). A phase II study evaluating the safety and efficacy of an adenovirus-δLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma. Annals of Oncology, 23(4), 997–1005. https://doi.org/10.1093/annonc/mdr341
57. Lin, C.-L., Lo, W.-F., Lee, T.-H., et al. (2002). Immunization with Epstein-Barr virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma. Cancer Research, 62(23), 6952–6958.
58. Weber, J. S., Yang, J. C., Atkins, M. B., & Disis, M. L. (2015). Toxicities of immunotherapy for the practitioner. Journal of Clinical Oncology, 33(18), 2092–2099. https://doi.org/10.1200/JCO.2014.60.0379
59. Yang, L., Yu, H., Dong, S., Zhong, Y., & Hu, S. (2017). Recognizing and managing toxicities in cancer immunotherapy. Tumor Biology, 39(3). https://doi.org/10.1177/1010428317694542
60. Satti, I., Meyer, J., Harris, S. A., Thomas, Z.-R. M., Griffiths, K., Antrobus, R. D., Rowland, R., Ramon, R. L., Smith, M., Sheehan, S., Bettinson, H., & McShane, H. (2014). Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: A phase 1, double-blind, randomised controlled trial. The Lancet Infectious Diseases, 14(10), 939–946. https://doi.org/10.1016/S1473-3099(14)70845-X
61. Chung, D.-S., Kim, C.-H., & Hong, Y.-K. (2012). Animal models for vaccine therapy. Advances in Experimental Medicine and Biology, 746, 143–150. https://doi.org/10.1007/978-1-4614-3146-6_11
62. Busson, P., Ganem, G., Flores, P., Mugneret, F., Clausse, B., Caillou, B., Braham, K., Wakasugi, H., Lipinski, M., & Tursz, T. (1988). Establishment and characterization of three transplantable EBV-containing nasopharyngeal carcinomas. International Journal of Cancer, 42(4), 599–606. https://doi.org/10.1002/ijc.2910420422
63. Hoe, S. L., Tan, L. P., Abdul Aziz, N., et al. (2017). CD24, CD44 and EpCAM enrich for tumour-initiating cells in a newly established patient-derived xenograft of nasopharyngeal carcinoma. Scientific Reports, 7(1), 12372. https://doi.org/10.1038/s41598-017-12045-8
64. Hoe, S. L. L., Tan, L. P., Jamal, J., Peh, S. C., Ng, C. C., Zhang, W. C., Ahmad, M., & Khoo, A. S. B. (2014). Evaluation of stem-like side population cells in a recurrent nasopharyngeal carcinoma cell line. Cancer Cell International, 14(1), Article 101. https://doi.org/10.1186/s12935-014-0101-0
65. Smith, P. A., Merritt, D., Barr, L., & Thorley-Lawson, D. A. (2011). An orthotopic model of metastatic nasopharyngeal carcinoma and its application in elucidating a therapeutic target that inhibits metastasis. Genes & Cancer, 2(11), 1023–1033. https://doi.org/10.1177/1947601912440878
66. Fu, T., Kui, S. V., & Wang, R.-F. (2004). Critical role of EBNA1-specific CD4+ T cells in the control of mouse Burkitt lymphoma in vivo. The Journal of Clinical Investigation, 114(4), 542–550. https://doi.org/10.1172/JCI200422053
67. Li, J., Chen, Q.-Y., He, J., Li, Z.-L., Tang, X.-F., Chen, S.-P., Xie, C.-M., Li, Y.-Q., Huang, L.-X., Ye, S.-B., Ke, M.-L., Tang, L.-Q., Liu, H., Zhang, L., Guo, S.-S., Xia, J.-C., Zhang, X.-S., Zheng, L.-M., Guo, X., Qian, C.-N., Mai, H.-Q., & Zeng, Y.-X. (2015). Phase I trial of adoptively transferred tumor-infiltrating lymphocyte immunotherapy following concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. OncoImmunology, 4(2), 1–10. https://doi.org/10.4161/23723556.2014.976507
68. Szturz, P., & Vermorken, J. B. (2017). Immunotherapy in head and neck cancer: Aiming at EXTREME precision. BMC Medicine, 15(1). https://doi.org/10.1186/s12916-017-0879-4
69. Lee, A. W. M., Ma, B. B. Y., Ng, W. T., & Chan, A. T. C. (2015). Management of nasopharyngeal carcinoma: Current practice and future perspective. Journal of Clinical Oncology, 33(29), 3356–3364. https://doi.org/10.1200/JCO.2015.60.9347
70. Kenney, S. C., & Mertz, J. E. (2014). Regulation of the latent-lytic switch in Epstein-Barr virus. Seminars in Cancer Biology, 26, 60–68. https://doi.org/10.1016/j.semcancer.2014.01.002
71. Young, L. S., & Dawson, C. W. (2014). Epstein-Barr virus and nasopharyngeal carcinoma. Chinese Journal of Cancer, 33(12), 581–590. https://doi.org/10.5732/cjc.014.10197
72. Houali, K., Wang, X., Shimizu, Y., Djennaoui, D., Nicholls, J., Fiorini, S., Bouguermouh, A., & Ooka, T. (2007). A new diagnostic marker for secreted Epstein-Barr virus-encoded LMP1 and BARF1 oncoproteins in the serum and saliva of patients with nasopharyngeal carcinoma. Clinical Cancer Research, 13(17), 4993–5000. https://doi.org/10.1158/1078-0432.CCR-06-2945
73. Chan, K. A., Woo, J. K., King, A., et al. (2017). Analysis of plasma Epstein-Barr virus DNA to screen for nasopharyngeal cancer. The New England Journal of Medicine, 377(6), 513–522. https://doi.org/10.1056/NEJMoa1701717
74. Teow, S., Liew, K., Khoo, A. S., & Peh, S. (2017). Pathogenic role of exosomes in Epstein-Barr virus (EBV)-associated cancers. International Journal of Biological Sciences, 13(10), 1276–1286. https://doi.org/10.7150/ijbs.19531
75. Rebbeck, T. R. (2014). Precision prevention of cancer. Cancer Epidemiology, Biomarkers & Prevention, 23(12), 2713–2715. https://doi.org/10.1158/1055-9965.EPI-14-1058
76. Xu, F.-H., Xiong, D., Xu, Y.-F., Cao, S.-M., Xue, W.-Q., Qin, H.-D., Liu, W.-S., Cao, J.-Y., Zhang, Y., Feng, Q.-S., Chen, L.-Z., Li, M.-Z., Liu, Z.-W., Liu, Q., Hong, M.-H., Shugart, Y. Y., Zeng, Y.-X., Zeng, M.-S., & Jia, W.-H. (2012). An epidemiological and molecular study of the relationship between smoking, risk of nasopharyngeal carcinoma, and Epstein-Barr virus activation. Journal of the National Cancer Institute, 104(18), 1396–1410. https://doi.org/10.1093/jnci/djs320
77. Shi, Y., Peng, S. L., Yang, L. F., Chen, X., Tao, Y. G., & Cao, Y. (2016). Co-infection of Epstein-Barr virus and human papillomavirus in human tumorigenesis. Chinese Journal of Cancer, 35.